Last reviewed · How we verify
Apatinib Capecitabine Oxaliplatin
This combination uses apatinib to inhibit vascular endothelial growth factor receptor (VEGFR) signaling while capecitabine and oxaliplatin provide chemotherapy to target cancer cells.
This combination uses apatinib to inhibit vascular endothelial growth factor receptor (VEGFR) signaling while capecitabine and oxaliplatin provide chemotherapy to target cancer cells. Used for Gastric cancer or gastroesophageal junction cancer (Phase 3 investigation), Advanced solid tumors (investigational).
At a glance
| Generic name | Apatinib Capecitabine Oxaliplatin |
|---|---|
| Sponsor | Hebei Medical University |
| Drug class | Tyrosine kinase inhibitor + chemotherapy combination |
| Target | VEGFR-2 (apatinib); thymidylate synthase (capecitabine); DNA (oxaliplatin) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Apatinib is a tyrosine kinase inhibitor that blocks VEGFR-2, reducing tumor angiogenesis and vascular permeability. Capecitabine is a fluoropyrimidine prodrug that converts to 5-FU for DNA synthesis inhibition, while oxaliplatin is a platinum agent causing DNA cross-linking. The combination leverages anti-angiogenic and cytotoxic mechanisms for enhanced anticancer activity.
Approved indications
- Gastric cancer or gastroesophageal junction cancer (Phase 3 investigation)
- Advanced solid tumors (investigational)
Common side effects
- Hand-foot skin reaction
- Neutropenia
- Nausea and vomiting
- Hypertension
- Diarrhea
- Peripheral neuropathy
Key clinical trials
- A Clinical Study To Evaluate Camrelizumab (SHR-1210) Plus Capecitabine and Oxaliplatin Followed by Sequential Treatment With Camrelizumab Plus Apatinib Mesylate in Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJ) Without Prior Systemic Therapy (PHASE3)
- Individualized Comprehensive Treatment for Advanced Hepatocellular Carcinoma (NA)
- Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular Subtyping (PHASE2)
- Apatinib for Resectable Colorectal Cancer (NA)
- PD-1 Inhibitors Combined With VEGF Inhibitors for Locally Advanced dMMR/MSI-H Colorectal Cancer (PHASE2)
- First-line Apatinib Combined With Tislelizumab and Chemotherapy for Advanced GC (PHASE2)
- A Study of SHR-1210 in Combination With Capecitabine + Oxaliplatin or Apatinib in Treatment of Advanced Gastric Cancer (PHASE2)
- Efficacy and Safety of Apatinib Combined With S-1 for Patients With Advance Gastric Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Apatinib Capecitabine Oxaliplatin CI brief — competitive landscape report
- Apatinib Capecitabine Oxaliplatin updates RSS · CI watch RSS
- Hebei Medical University portfolio CI